Q-omics provides the consensus-scored NR2C2AP profile across patient tissues and cancer cell-line models. NR2C2AP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NR2C2AP is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, NR2C2AP RNA expression shows 19,489 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where NR2C2AP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR2C2AP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR2C2AP survival associations across molecular data types. NR2C2AP RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR2C2AP RNA expression–survival associations across cancer types. High NR2C2AP expression shows unfavorable associations in ACC, LIHC, KICH and LGG, but favorable associations in HNSC and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NR2C2AP RNA expression.
This table summarizes NR2C2AP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NR2C2AP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR2C2AP shows higher tumor expression in COAD, HNSC, KIRC, KIRP, BLCA and LUAD. The COAD box plot shows higher NR2C2AP RNA expression in tumor versus normal tissue (log2 FC = +1.384, t-test p < 0.001).
This table shows molecular features associated with NR2C2AP in patient tissues and cancer cell lines. In patient samples, NR2C2AP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NR2C2AP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
